Send me a link:

*Text messaging rates may apply.

 Dow Up0.35% Nasdaq Up0.59%

More On ACL.AX



News & Info


Analyst Coverage


  • Major Holders
  • Insider Transactions
  • Insider Roster


Alchemia Limited (ACL.AX)

0.63 0.00(0.00%) 12:40AM EDT
ProfileGet Profile for:
Alchemia Limited
3 Hi
Eight Mile Plains
Brisbane, QLD 4113
Australia - Map
Phone: 61 7 3340 0200
Fax: 61 7 3340 0222

Index Membership:N/A
Full Time Employees:24

Business Summary 

Alchemia Limited, a biotechnology company, is engaged in the discovery and development of human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies primarily in Australia. The company’s technologies include HyACT drug delivery technology that enhances the delivery of chemotherapeutic agents to cancer cells; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. It also provides generic fondaparinux, an injectable anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, the company develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer. It has collaboration with Monash Institute of Pharmaceutical Science to discover drug candidates for G-Protein coupled receptors; and University of Queensland to discover novel opioid analgesics with reduced side effects. The company was founded in 1995 and is headquartered in Brisbane, Australia.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Alchemia Limited

Key Executives 
Dr. Tracie Ramsdale Ph.D., 51
Co-Founder, Chairman of Scientific Advisory Board, Non-Exec. Director, Chairman of Remuneration Committee, Chairman of Audit & Risk Committee, Member of Nomination Committee and Member of Due Diligence Committee
Mr. Imran Ahamed CPA, ACMA, CGMA ,
Group Financial Controller
Dr. Tracey Jean Brown B.Sc., Ph.D., 51
Chief Scientific Officer and VP of Oncology
Dr. Goslik Schepers Ph.D.,
VP of Bus. Devel.
Dr. Wim D. F. Meutermans Ph.D.,
VP of Drug Discovery
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in AUD.